Weekly, Mon 9 Nov: A survival win, a billion-dollar deal, an Ebola push. What's real?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
Akeso’s ivonescimab, Genrix’s early lupus data and Ebola vaccine candidates: evidence, money and delivery across this week’s East–West biotech news. China review is not approval; early uncontrolled lupus responses are not comparative benefit.
Full transcript and all sources for this episode
Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil reports no holdings in companies mentioned.
Research cut: 9 Nov 2026, 05:55:43 SGT. Weekly retrospective: 2–8 Nov.
0:00 Introduction and AI-voice disclosure
1:15 Akeso: evidence versus review
5:16 Hemay and deal payment structures
9:32 iX: licences and the next document
10:45 Ebola: trial evidence and delivery
13:41 BionicM, Mindtrix and egg proteins
19:40 Genrix: early lupus evidence
21:13 The next evidence to watch
Key sources: Akeso: China priority review, 5 Nov; WHO: Tumaini candidates, 4 Nov; China lupus trial registry; Cullinan: interim China lupus data, 8 Nov. Sponsor-reported interim lupus data and all original sources are linked in the transcript.
Weekly roundup: subscribe to The East–West Bio Brief on LinkedIn.
Also listen on Apple Podcasts, Amazon Music and YouTube.
Which uncertainty did an announcement actually remove—and what evidence should come next?